Moderator
Prof. Juliana Chan
- Professor of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong (CUHK), Hong Kong
Speaker
Prof. Didac Mauricio
- Professor of Medicine, Faculty of Medicine, University of Vic & Central University of Catalonia (UVic/UCC), Barcelona, Spain
Dr. Peter Chun-Yip Tong
- Specialist in Endocrinology, Diabetes & Metabolism
Prof. Elaine Chow
- Associate Professor, Faculty of Medicine, CUHK
Diabetes mellitus (DM) remains a global health challenge, with insulin therapy playing a pivotal role in managing the condition. Insulin glargine U300 (Gla-300), a second-generation basal insulin analogues has emerged as a transformative treatment option, offering an improved glycaemic control and reduced hypoglycaemia risk among patients with DM compared to earlier insulin formulations.
On 4th March 2025, world-renowned healthcare experts in Endocrinology gathered at the Regency Ballroom, Hyatt Regency, Hong Kong, organised by the Association of Hong Kong Diabetes Nurses (AHKDN) and the Diabetes Hongkong (DHK) for an insightful professional symposium on the clinical and practical aspects of Gla-300. Prof. Juliana Chan, a professor of Medicine at the CHUK made an opening remark emphasising the importance of insulin in diabetes management This was then followed by one of the key speakers, Prof. Didac Mauricio, a world-renowned endocrine specialist from the UVic/UCC who delivered a comprehensive presentation titled "Transforming Diabetes Outcomes: The Clinical Power of Insulin Glargine U300". He emphasised the robust clinical evidence supporting the efficacy and safety of Gla-300, and its role in improving patient outcomes. Next, Dr. Peter CY Tong, a specialist in Endocrinology, Diabetes & Metabolism, shared his practical insights on the initiation, titration and persistence of Gla-300. This was followed by Prof. Elaine Chow, who presented her findings on transitioning patients from neutral protamine Hagedorn (NPH) insulin to Gla-300 and the compelling data on the benefits of using Gla-300 clinically.
Following the presentations, an interactive Q&A and panel discussion ensued on the real-world application of Gla-300 and the benefit of basal insulin analogous over NPH. Finally, the symposium concluded with a closing remark by Prof. Chan that reiterated the importance of leveraging advanced therapies like Gla-300 to elevate diabetes care standards.
Organised by:
